Does Utah Medicaid cover Ozempic or Wegovy or Rybelsus for weight loss?

Other indications only. Wegovy has its own prior authorization routes for a history of a major adverse cardiovascular event and for MASH, both for adults. The obesity route is reauthorization only and was capped at 30 June 2026

Does Utah Medicaid cover Mounjaro or Zepbound for weight loss?

Other indications only. Zepbound has a prior authorization route for moderate to severe obstructive sleep apnea in adults. The obesity route is reauthorization only and was capped at 30 June 2026

Medicaid coverage

Utah: what Medicaid covers

Utah is the one state on this grid with a coverage cliff already behind it. Its prior authorization form covers Wegovy for cardiovascular risk and for MASH, and Zepbound for obstructive sleep apnea, and those routes are unaffected. Weight loss was different: it was a legislative pilot, it was open only to people who already held a weight-loss authorization granted between 1 July 2025 and 30 June 2026, and the form makes the prescriber attest they know coverage may not continue past 30 June 2026. That date has passed. The form is still the one Utah serves and it was last updated on 1 June 2026, but the state has published nothing saying what happened on 1 July, so the weight-loss answer here is genuinely unresolved rather than negative.

Checked against the primary source August 28, 2026

What Medicaid in Utah covers, and the criteria that apply.
Drug	Position	Criteria
Semaglutide	Other indications only	Wegovy has its own prior authorization routes for a history of a major adverse cardiovascular event and for MASH, both for adults. The obesity route is reauthorization only and was capped at 30 June 2026
Tirzepatide	Other indications only	Zepbound has a prior authorization route for moderate to severe obstructive sleep apnea in adults. The obesity route is reauthorization only and was capped at 30 June 2026
Liraglutide	not checked	Saxenda appears only in the obesity category, which is reauthorization only and was capped at 30 June 2026. Utah has published nothing since that date saying whether it continued

Semaglutide Other indications only

Wegovy has its own prior authorization routes for a history of a major adverse cardiovascular event and for MASH, both for adults. The obesity route is reauthorization only and was capped at 30 June 2026
Tirzepatide Other indications only

Zepbound has a prior authorization route for moderate to severe obstructive sleep apnea in adults. The obesity route is reauthorization only and was capped at 30 June 2026
Liraglutide not checked

Saxenda appears only in the obesity category, which is reauthorization only and was capped at 30 June 2026. Utah has published nothing since that date saying whether it continued

If the answer is no. Around 45% of initial prior authorizations for these drugs are refused, and 35 to 45% of first-level appeals are overturned. A refusal is not the end of the process, and the cash-pay routes are priced on this site alongside it.

Sources

Every claim above is checked against the primary text, and the date is the day we last opened it.

1
Utah Medicaid Fee-for-Service Preferred Drug List (PDL) & Pharmacy Coverage Resources, Effective July 1, 2026
Utah Department of Health and Human Services, Utah Medicaid (read from the state’s archived copy) Primary text read and checked Checked August 27, 2026
2
Utah Medicaid Pharmacy Prior Authorization Request Form: GLP-1 Medications for Weight-related Comorbidities (Saxenda, Wegovy, Zepbound), Last Updated 6-1-26
Utah Department of Health and Human Services, Utah Medicaid (read from the state’s archived copy) Primary text read and checked Checked August 27, 2026